Keywords: vernalis, leaps, 400m, frova, deal, usa-based, endo

Vernalis leaps 104% on $400M Frova deal

Article | 26 July 2004

Print This

USA-based Endo Pharmaceuticals says it has entered into a deal toacquire North American marketing rights for the migraine drug Frova ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in